Skip to main content

Rabbit Recombinant Monoclonal MGAT1 antibody. Suitable for WB and reacts with Human samples. Cited in 11 publications.


Images

Western blot - Anti-MGAT1 antibody [EPR14247] (AB180578), expandable thumbnail
  • Western blot - Anti-MGAT1 antibody [EPR14247] (AB180578), expandable thumbnail
  • Western blot - Anti-MGAT1 antibody [EPR14247] (AB180578), expandable thumbnail

Publications

Key facts

Isotype
IgG
Host species
Rabbit
Storage buffer

Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA

Form
Liquid
Clonality
Monoclonal

Immunogen

  • The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

Select an application
Product promiseTestedExpectedPredictedNot recommended
WB
Human
Tested

Tested
Tested

Species
Human
Dilution info
1/1000 - 1/10000
Notes

-

Target data

Function

Initiates complex N-linked carbohydrate formation. Essential for the conversion of high-mannose to hybrid and complex N-glycans.

Alternative names

GGNT1, GLCT1, GLYT1, MGAT, MGAT1, N-glycosyl-oligosaccharide-glycoprotein N-acetylglucosaminyltransferase I, GNT-I, GlcNAc-T I

Recommended products

Rabbit Recombinant Monoclonal MGAT1 antibody. Suitable for WB and reacts with Human samples. Cited in 11 publications.

Key facts

Isotype
IgG
Form
Liquid
Clonality
Monoclonal
Immunogen
  • The exact immunogen used to generate this antibody is proprietary information.
Clone number
EPR14247
Purity
Tissue culture supernatant
Concentration
Loading...

Storage

Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Notes

Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

MGAT1 also known as mannosyl (α-13-)-glycoprotein β-12-N-acetylglucosaminyltransferase is an enzyme with a molecular mass of approximately 51 kDa. It is a critical component of the N-glycosylation process in eukaryotic cells. This protein resides primarily in the Golgi apparatus where it acts as a glycosyltransferase enzyme. MGAT1 catalyzes the transfer of N-acetylglucosamine to the mannose residues on the glycan chain which is an important step in forming complex N-glycans. This modification impacts several cellular functions.

Biological function summary

MGAT1 plays an essential role in protein folding stability and function by modifying N-glycans attached to nascent proteins. The enzyme acts as part of a complex that includes other enzymes like MGAT2 MGAT3 and MGAT5 in the glycan biosynthesis pathway. MGAT1's activity significantly influences cell-cell communication signaling and immune responses. Its function enhances the diversity and biological roles of glycoproteins within cells impacting various physiological processes.

Pathways

MGAT1 is a significant player in the protein glycosylation and folding pathways. It interacts with proteins like MGAT2 and galectin-3 indicating its involvement in broader metabolic processes. N-glycan biosynthesis pathway is its primary pathway where it contributes by enabling the elongation and branching of N-glycan structures. This glycosylation process affects cellular processes such as signal transduction and protein trafficking through downstream effects on glycoproteins.

Associated diseases and disorders

MGAT1 has implications in congenital disorders of glycosylation and cancer. Abnormal MGAT1 activity leads to improper glycosylation causing congenital disorders that affect multiple systems including nervous and digestive systems. In cancer MGAT1-linked glycan alterations on surface proteins contribute to tumor progression and metastasis. Disrupted interactions with proteins like MGAT5 can increase cell surface glycoprotein complexity promoting cancer cell survival and immune evasion.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

3 product images

  • Western blot - Anti-MGAT1 antibody [EPR14247] (ab180578), expandable thumbnail

    Western blot - Anti-MGAT1 antibody [EPR14247] (ab180578)

    All lanes: Western blot - Anti-MGAT1 antibody [EPR14247] (ab180578) at 1/10000 dilution

    All lanes: HeLa cell lysate at 20 µg

    Secondary

    All lanes: Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugate at 1/1000 dilution

    Predicted band size: 51 kDa

  • Western blot - Anti-MGAT1 antibody [EPR14247] (ab180578), expandable thumbnail

    Western blot - Anti-MGAT1 antibody [EPR14247] (ab180578)

    All lanes: Western blot - Anti-MGAT1 antibody [EPR14247] (ab180578) at 1/2000 dilution

    All lanes: 293 cell lysate at 20 µg

    Secondary

    All lanes: Goat Anti-Rabbit igG, (H+L), Peroxidase conjugate at 1/1000 dilution

    Predicted band size: 51 kDa

  • Western blot - Anti-MGAT1 antibody [EPR14247] (ab180578), expandable thumbnail

    Image collected and cropped by CiteAb under a CC-BY license from the publication

    Western blot - Anti-MGAT1 antibody [EPR14247] (ab180578)

    MGAT1 western blot using anti-MGAT1 antibody [EPR14247] ab180578. Publication image and figure legend from Fisher, P., Spencer, H., et al., 2019, Cell Rep, PubMed 31018136.


    ab180578 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab180578 please see the product overview.

    Predicting Organizational Changes in Trafficking Defective Cell Lines(A and B) Observed and simulated glycan profiles of Cog4KD HeLa cell lines (A) and Cog4KO HEK293T cell lines (B). Error bars for glycan profiling are SEM for n = 3.(C) Total effective enzymatic rate changes predicted by the model following fitting as a result of Cog4 perturbation. The x axis is on a log scale. Error bars for total effective enzymatic rates and distributions are SD for n = 20 (Cog4KD HeLa) and n = 21 (Cog4KO HEK293T) individual fitting procedures.(D) Western blot analysis of endogenous MGAT1, GalT, and FUT8 and quantification normalized to WT HEK293T. Error bars for western blot quantification are SD for n = 3. ns, not significant; ∗p < 0.05 for a Student’s t test.(E) Predicted relative distribution of MAN1 following the fitting of WT and Cog4KD HeLa glycan profiles.(F) Predicted relative distributions of selected enzymes in WT and Cog4KO HEK293T cells in each cisterna normalized to the total predicted effective enzymatic rate for each enzyme for each cell line.(G) Airyscan confocal microscopy of GM130 and exogenous GalT-YFP in nocodazole-treated WT and Cog4KO HEK293T cell lines.(H) Pearson’s correlation coefficient for WT and Cog4KO HEK293T cells. Pearson’s correlation coefficients were calculated for each Golgi stack, and error bars are SD for n = 4 cells with 151 (WT) and 131 (Cog4KO) stacks. ∗∗∗p < 0.001 for a Student’s t test.See also Figures S3 and S6 and Table S3.

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com